Genentech

This World IBD Day we’re recognizing everyone who is impacted by or connected to Inflammatory Bowel Disease (IBD). Living with IBD isn't a solo journey. Many aspects of this chronic and complex condition are not visible and can be misunderstood. From researchers and gastroenterologists to patients’ support networks, effective IBD management requires collaboration. We are committed to being part of this community by driving important conversations to better support patients and by advancing care. #WorldIBDDay

We’re building on our 50-year journey and presenting new data across breast, lung, gastrointestinal, bladder and blood cancers at American Society of Clinical Oncology (ASCO). Our science is grounded in the realities of everyday care and focused on reducing treatment burden to ensure innovative therapies reach patient communities. Learn more about our efforts to transform cancer care: http://spr.ly/6041BBA3iT #ASCO26

The FDA approved our immunotherapy as an adjuvant treatment for adults with muscle-invasive bladder cancer (#MIBC) after surgery (cystectomy) who have circulating tumor DNA (ctDNA) molecular residual disease as determined by an FDA authorized test. Learn more about how we’re advancing precision medicine options: http://spr.ly/6048BBLyUr

The loudest cheers aren’t always for the team on the field. Sometimes, they’re for the people beside us. For 50 years, Genentech has worked to help advance medicine so more patients can experience the moments that matter most — from game days and family traditions to simply being there together. #TheOriginalBiotech #Genentech50

Our CEO Ashley Magargee recently sat down with Moira Gunn, the host of #BioTechNation podcast, for a candid conversation on our legacy, and what it will take to shape the next 50 years. Tune in to hear how we’re combining pioneering science, advanced technology, and a track record of breakthroughs to lead the next era of patient impact. #TheOriginalBiotech https://lnkd.in/g_Av7fMX

Groundbreaking science only fulfills its promise when it can reach the communities who need it most. Kudos to this team for their bold thinking and for setting new standards in the pursuit of a healthier future.

#Breaking: The FDA approved our treatment for relapsing-remitting multiple sclerosis (RRMS) in pediatric patients 10 years of age and older who weigh 55 pounds or more. This approval represents an important milestone for children living with MS in the U.S. and their families, and can help close the longstanding gap in treatment options for children aged 10 and older. We look forward to continuing our commitment to the MS community and helping improve the lives of those living with this chronic condition. Learn more: http://spr.ly/6047BBml1R

Congratulations to Gina Wang for being honored as one of the Most Influential Women in Bay Area Business! As our Senior Director of Research in Discovery Chemistry and Drug Discovery, Gina has opened new avenues for drug discovery, including a new treatment class for breast cancer. This recognition from San Francisco Business Times honors her legacy across chemistry, biology, pharmacology and more. Thank you, Gina, for all your contributions to our work in breast cancer advancing treatments for patients who need them most, and to scientific research as a whole! http://spr.ly/6048BBlaCq

It takes an average of 6 years for people living with #lupus to receive a proper diagnosis. That can mean years of searching for answers while the disease progresses, often due to subtle symptoms that are easy to miss. Earlier recognition is critical, not just for diagnosis, but for helping patients access the right care and treatment sooner. While steroids have long played an important role in helping manage inflammation in lupus, understanding both their benefits and potential side effects remains an important part of treatment decisions. This #WorldLupusDay, we’re committed to advancing education and awareness to help drive earlier recognition and more informed approaches to care. Explore the latest insights on lupus management and treatment innovation: http://spr.ly/6044BBYj0M #LupusAwarenessMonth

Following the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, our very own Hugh Lin, MD MBA reflected on the breakthroughs and high-impact conversations shared at #ARVO2026. Explore his perspective from the ground, and what these scientific milestones could mean for the future of care in retinal diseases like wet age-related macular degeneration and diabetic macular edema.